Form 4 for IKT Inhibikase Therapeutics, Inc.
Accepted 2024-10-23 00:00:00 ET · period of report 2024-10-21 · accession 0000950170-24-116785 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2024-10-23 | 2024-10-21 | IKT | Bellini Roberto | Dir | P - Purchase | $1.37 | +1.46M | 1.46M | New | +$2.00M |
| D | 2024-10-23 | 2024-10-21 | IKT | Bellini Roberto | Dir | A - Grant | $0.00 | +60.0K | 60.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-21 | P | A | 1,460,000 | $1.37 | 1,460,000 | I See footnote | — | — | (F1) These securities are owned directly by BSQUARED CAPITAL INC ("BSQ"). Mr. Bellini is a shareholder and officer of BSQ. Mr. Bellini expressly disclaims beneficial ownership of the securities listed above except to the extent of any pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| 2 | Derivative | Stock Option (right to buy) | 2024-10-21 | A | A | 60,000 | $0.00 | 60,000 | D | $2.22 · — to 2034-10-21 | 60,000 Common Stock | (F2) The option shares vest 50% on each of the first two anniversaries of October 21, 2024. |